Angelos K. Koutras, Ioannis Starakis, Dionysia Lymperatou and Haralabos P. Kalofonos Pages 1230 - 1238 ( 9 )
Current evidence indicates that angiogenesis plays an important role in the pathogenesis of several malignancies, including breast cancer. Bevacizumab is a monoclonal antibody that targets the vascular endothelial growth factor (VEGF). Recent clinical data have demonstrated that the addition of bevacizumab to first-line chemotherapy improves the progression-free survival of patients with advanced breast cancer. This review presents an update on the role of bevacizumab, as well as other anti-angiogenic agents in the management of patients with breast carcinoma.
Angiogenesis, bevacizumab, breast cancer, treatment.
Division of Oncology, Department of Medicine, University Hospital of Patras, 26504 Rion-Patras, Greece